FOUNTAIN HILLS, Ariz., Jan. 13, 2011 /PRNewswire/ -- Sunridge International (OTC Bulletin Board: SNDZ), announced today that it plans to open company owned glaucoma clinics for the use of its patented treatment Pneumatic Trabeculoplasty (PNT).
As a manufacturer, Sunridge currently relies on its distributor network for sales. Though the company is in the process of expanding its distributor network, it is still reliant on others to provide profitability for the company. It is the company's intent to take advantage of its patented procedure by initiating glaucoma clinics under its direct control. By doing so, Sunridge can capitalize not only on the sales of its equipment and disposable product line to others, but also a direct revenue source from our clinics for the medical treatment itself.
Sunridge is currently raising money to open its first clinic. Based on past experience our projections for the clinic would indicate that it would be cash flow positive by its fourth month of operation. Once successful with the first clinic, Sunridge intends to raise capital for the rapid expansion of additional company owned clinics. This new direction in the company's business plan allows us to take direct charge of our future and accelerate profitability for the company.
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International www.oi-pnt.com.CONTACT:Jeff Smith Sunridge InternationalT: +1-480-837-6165e-mail: '/>"/>